Table 3.
Multivariable model to predict time to first CLL therapy and overall survival
| Characteristic | TFT | OS | |||
|---|---|---|---|---|---|
| HR (95% C.I.) | p-value | HR (95% C.I.) | p-value | ||
| Age1 | 1.0 (0.99–1.0) | 0.56 | 1.1 (1.0–1.1) | <0.0001 | |
| Male Sex | 1.6 (1.1–2.3) | 0.01 | 1.1 (0.6–2.1) | 0.66 | |
| Rai Risk Category | |||||
| Intermediate (stage I/II)2 | 3.0 (2.1–4.4) | <0.0001 | 1.7 (0.9–3.1) | 0.08 | |
| High (stage III/IV)2 | 15.3 (8.4–28.0) | <0.0001 | 6.1 (2.1–17.9) | 0.001 | |
| IGHV unmutated | 2.6 (1.8–3.8) | <0.0001 | 1.9 (0.99–3.7) | 0.06 | |
| FISH risk category | |||||
| deletion 11q/17p3 | 1.4 (0.9–2.3) | 0.13 | 3.7 (1.7–7.8) | 0.001 | |
| trisomy 123 | 1.0 (0.7–1.5) | 0.96 | 1.8 (0.9–3.8) | 0.12 | |
| Hypogammaglobulinemia | 1.5 (1.1–2.2) | 0.02 | 0.9 (0.5–1.6) | 0.67 | |
1
for each year older
2
relative to Rai 0
3
relative to no detectable FISH abnormality or del13q as the sole abnormality
Abbreviations Used:
TFT: Time to first therapy; OS; overall survival; HR=hazard ratio; C.I. =confidence interval